This method paper used boron-doped carbon quantum dots as a fluorescent probe to measure the drug elagolix in human plasma and tablets, with a limit of quantitation of 1.74 ng/mL for the drug. Boron is a dopant in the probe, not an analyte.
Key numbers
- This paper reports no numerical findings relevant to boron exposure.
Methods (brief)
Spectrofluorimetric assay with boron-doped carbon quantum dots; validation and a pharmacokinetic application in plasma.
Evidence fitness
Boron appears here only as a component of an engineered material. The paper does not support dietary exposure or toxicity claims for boron.
Limitations
Off-topic for boron exposure; no boron measurements in food, water or people. Funded through the Egyptian STDF open access program; no conflicts declared.
Related evidence
Update history
No substantive edit history is available in this build. The full commit record is available in git.